Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 2,140 shares at $232.15 ($499K) on 2021-08-16, disclosed to the SEC on 2021-08-18.
Open-market sale of $499k NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $223.26 | 55 | $12K | 2.5% |
| 2 | $225.98 | 57 | $13K | 2.6% |
| 3 | $227.79 | 141 | $32K | 6.4% |
| 4 | $228.79 | 101 | $23K | 4.6% |
| 5 | $230.00 | 219 | $50K | 10.1% |
| 6 | $231.27 | 204 |
| $47K |
| 9.4% |
| 7 | $232.15 | 274 | $64K | 12.7% |
| 8 | $232.15 | 274 | $64K | 12.7% |
| 9 | $233.17 | 153 | $36K | 7.1% |
| 10 | $234.38 | 177 | $41K | 8.3% |
| 11 | $234.88 | 13 | $3K | 0.6% |
| 12 | $236.22 | 48 | $11K | 2.3% |
| 13 | $237.92 | 63 | $15K | 3.0% |
| 14 | $239.32 | 61 | $15K | 2.9% |
| 15 | $240.37 | 78 | $19K | 3.8% |
| 16 | $242.99 | 107 | $26K | 5.2% |
| 17 | $244.99 | 50 | $12K | 2.5% |
| 18 | $246.72 | 51 | $13K | 2.5% |
| 19 | $248.98 | 14 | $3K | 0.7% |
| Total | $233.35 avg | 2,140 | $499K | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |